Innovations in Surgical Oncology
Transcript of Innovations in Surgical Oncology
![Page 1: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/1.jpg)
Innovations in Surgical OncologyInnovations in Surgical Oncology
Sricharan Chalikonda, M.D.Surgical Oncology
Director Gen.Surg Robotics ProgramCleveland Clinic
Sricharan Chalikonda, M.D.Surgical Oncology
Director Gen.Surg Robotics ProgramCleveland Clinic
![Page 2: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/2.jpg)
DisclosuresDisclosures
CovidienSpeaker
BardSpeaker
Intuitive SurgicalProctorSpeaker
CovidienSpeaker
BardSpeaker
Intuitive SurgicalProctorSpeaker
![Page 3: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/3.jpg)
Surgical Oncology ProgramsSurgical Oncology Programs
CarcinomatosisHIPEC
SarcomaResection with HAM catheters
Minimally Invasive/Robotic Approaches
CarcinomatosisHIPEC
SarcomaResection with HAM catheters
Minimally Invasive/Robotic Approaches
![Page 4: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/4.jpg)
Peritoneal CarcinomatosisPeritoneal Carcinomatosis
Progressive involvement of peritoneal surfaces by tumor seeded within peritoneal cavity
Rupture primary tumorSpillage tumor cells by surgical manipulation
Traditionally considered Stage IV diseaseTreated with systemic chemotherapySurgical treatment palliative for sympotomatic disease
Progressive involvement of peritoneal surfaces by tumor seeded within peritoneal cavity
Rupture primary tumorSpillage tumor cells by surgical manipulation
Traditionally considered Stage IV diseaseTreated with systemic chemotherapySurgical treatment palliative for sympotomatic disease
![Page 5: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/5.jpg)
Gastric~11,000
Colon~17,000
Appendiceal~1100
Ovarian~20,000
Mesothelioma~500
Pseudomyxoma
Aggressiveness
Patient PopulationPatient Population
![Page 6: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/6.jpg)
Peritoneal Carcinomatosis-Natural History-
Peritoneal Carcinomatosis-Natural History-
Crampy abdominal painAnorexia/Weight lossBowel ObstructionAscitesInanitionInfectionDeath
Crampy abdominal painAnorexia/Weight lossBowel ObstructionAscitesInanitionInfectionDeath
![Page 7: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/7.jpg)
Major problem in cancer management
Hard to detect by imagingDifficult to manageMarked deterioration in quality of life Short survival
Major problem in cancer management
Hard to detect by imagingDifficult to manageMarked deterioration in quality of life Short survival
Peritoneal CarcinomatosisPeritoneal Carcinomatosis
![Page 8: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/8.jpg)
Treatment OptionsTreatment OptionsSurgical Treatment
Surgery with or without systemic chemotherapy has shown to be inadequate for the treatment of patients with PC.
Systemic ChemotherapyPoor penetration to peritoneum
Peritoneal Chemo Dwell
Surgical TreatmentSurgery with or without systemic chemotherapy has shown to be inadequate for the treatment of patients with PC.
Systemic ChemotherapyPoor penetration to peritoneum
Peritoneal Chemo Dwell
![Page 9: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/9.jpg)
Rationale: Cyto-Surgery + HIPEC Rationale: Cyto-Surgery + HIPEC
Cancer is confined to peritoneal cavitySurgeon can take down adhesions, cytoreduce tumorsHeat has effect on cancer cells“Targeting” and localizing the principal effect of a multi-modality treatment
Cancer is confined to peritoneal cavitySurgeon can take down adhesions, cytoreduce tumorsHeat has effect on cancer cells“Targeting” and localizing the principal effect of a multi-modality treatment
![Page 10: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/10.jpg)
Multi-Modality TreatmentMulti-Modality Treatment
CYTOREDUCTIVESURGERY
INTRAPERITONEAL HYPERTHERMIA
CHEMOTHERAPY
![Page 11: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/11.jpg)
Verwaal et al. 2003
![Page 12: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/12.jpg)
Verwaal et al. 2003
![Page 13: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/13.jpg)
![Page 14: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/14.jpg)
Improve SurvivalImprove SurvivalPeritonealCancer
Average Life expectancy with standard therapy
With “HIPEC”
Colon 6 mos. 18 – 36 mos.
AppendixPMP
10 mos.5 -10 yrs.
30 mos.10 – 20 yrs.
Mesothelioma 12 – 21 mos. 34 – 92 mos.
Ovarian 6 mos. 25 – 28 mos.
Gastric 1 mos. 14 – 24 mos.
![Page 15: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/15.jpg)
Before/After Cytoreductive Surgery
Before/After Cytoreductive Surgery
![Page 16: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/16.jpg)
![Page 17: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/17.jpg)
Cytoreductive SurgeryCytoreductive Surgery
The first and most important stepThe goal is to remove all visible disease.This would leave microscopic and small surface tumors.
The first and most important stepThe goal is to remove all visible disease.This would leave microscopic and small surface tumors.
![Page 18: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/18.jpg)
![Page 19: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/19.jpg)
![Page 20: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/20.jpg)
![Page 21: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/21.jpg)
![Page 22: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/22.jpg)
![Page 23: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/23.jpg)
![Page 24: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/24.jpg)
Approach to Patients with Peritoneal CarcinomatosisApproach to Patients with Peritoneal Carcinomatosis
Recommend Biopsy of nodules and peritoneal washingsNo need to resect primary unless perforatedNeoadjuvant chemo followed by cytoreductive surgery with HIPEC if possible
Recommend Biopsy of nodules and peritoneal washingsNo need to resect primary unless perforatedNeoadjuvant chemo followed by cytoreductive surgery with HIPEC if possible
![Page 25: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/25.jpg)
Retroperitoneal SarcomaRetroperitoneal Sarcoma
Usually grow to a large size before presentationRequire multivisceral resection to remove completelyHigh recurrence rate
Usually grow to a large size before presentationRequire multivisceral resection to remove completelyHigh recurrence rate
![Page 26: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/26.jpg)
Treatment OptionsTreatment Options
Neoadjuvant radiation followed by resection
Bowel and other structures protected by tumorDifficult to focus on margin
Resection followed by radiationBowel exposed to radiation which limits dose
Neoadjuvant radiation followed by resection
Bowel and other structures protected by tumorDifficult to focus on margin
Resection followed by radiationBowel exposed to radiation which limits dose
![Page 27: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/27.jpg)
Resection with periop radiationResection with periop radiation
Tumor resectedBowel packed awayCatheters placed at margin and radiation administered over next 36hoursComplete treatment achieved during one hospitalization
Tumor resectedBowel packed awayCatheters placed at margin and radiation administered over next 36hoursComplete treatment achieved during one hospitalization
![Page 28: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/28.jpg)
Case reportCase report
60 year old with abdominal fullness and vague pain
60 year old with abdominal fullness and vague pain
![Page 29: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/29.jpg)
Surgical ResectionSurgical Resection
ColectomyNephrectomyCholecystectomyPlacement of Catheters
ColectomyNephrectomyCholecystectomyPlacement of Catheters
![Page 30: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/30.jpg)
ResultResult
![Page 31: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/31.jpg)
RoboticsRobotics
![Page 32: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/32.jpg)
Robotic Liver ResectionRobotic Liver Resection
![Page 33: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/33.jpg)
Pancreatic SurgeryPancreatic Surgery
![Page 34: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/34.jpg)
Biliary DissectionBiliary Dissection
55 Year old female with abdominal pain. Found to have choledochol cyst during routine IOC.
55 Year old female with abdominal pain. Found to have choledochol cyst during routine IOC.
![Page 35: Innovations in Surgical Oncology](https://reader035.fdocuments.in/reader035/viewer/2022071600/613d2107736caf36b759a841/html5/thumbnails/35.jpg)
Thank YouThank YouStaff
Lisa TaylorSue DreesNancy Brown
PartnersMatt WalshBob PelleyPedro EscobarChad MichenerPeter RoseRich DrakeKevin Stephans
StaffLisa TaylorSue DreesNancy Brown
PartnersMatt WalshBob PelleyPedro EscobarChad MichenerPeter RoseRich DrakeKevin Stephans